Pathogenesis and treatment of calcium stones

Seminars in Nephrology

Volumn 16, Issue 5, 1996, Pages 398-411

  Parks, Joan H ^a   Coe, Fredric L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORTALIDONE; HYDROCHLOROTHIAZIDE; MAGNESIUM HYDROXIDE;

CALCIUM STONE; DIET THERAPY; DISEASE ASSOCIATION; ENTEROPATHY; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPERPARATHYROIDISM; HYPERURICOSURIA; IDIOPATHIC DISEASE; KIDNEY TUBULE ACIDOSIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ALLOPURINOL; ANTIMETABOLITES; BENZOTHIADIAZINES; CLINICAL TRIALS; DIURETICS; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM; PROGNOSIS; SODIUM CHLORIDE SYMPORTER INHIBITORS; URINARY CALCULI;

EID: 0029741168     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Coe FL, Parks JH. Familial (Idiopathic Hypercalciuria), in Coe, FL, Parks JH (eds): Nephrolithiasis: Pathogenesis and Treatment (ed 2). Chicago, IL, Year Book Medical Publishers, 1988, pp 108-138
2. Coe FL, Parks JH, Moore ES: Familial idiopathic hypercalciuria. N Engl J Med 300:337-340, 1979
3. Coe FL, Favus MJ: Disorders of Stone Formation, in Brenner BM, Rector FC, Jr (eds): The Kidney (ed 3). Philadelphia, PA, Saunders, 1986, pp 1403-1442
4. Lemann JJ: Pathogenesis of Idiopathic Hypercalciuria and Nephrolithiasis, in Coe FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York, NY, Raven Press, 1992, pp 685-706
5. Lawoyin S, Sismilich S, Browne R, et al: Bone mineral content in patients with calcium urolithiasis. Metabolism 28:1250-1254, 1979
6. Malluche HH, Tschoepe W, Ritz E, et al: Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 50:654-658, 1980
7. Barkin J, Wilson DR, Manuel MA, et al: Bone mineral content in idiopathic calcium nephrolithiasis. Miner Electrolyte Metab 11:19-24, 1985
8. Coe FL, Favus MJ, Crockett T, et al: Effects of lowcalcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH) 2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 72: 25-32, 1982
9. Hosking DH, Erickson SB, Van Den Berg CJ, et al: The stone clinic effect in patients with idiopathic calcium urolithiasis. J Urol 130:1115-1118, 1983
10. Wilson DR, Strauss AL, Manuel MA: Comparison of medical treatments for the prevention of recurrent calcium nephrolithiasis. Urol Res 12:39-40, 1984
11. Zerwekh JE, Sakhaee K, Breslau NA, et al: Impaired bone formation in male idiopathic osteoporosis: Further reduction in the presence of concomitant hypercalciuria. Osteoporos Int 2:128-134, 1992
12. Broadus AE, Insogna KL, Lang R, et al: Evidence for disordered control of 1,25 dihydroxyvitamin D production in absorptive hypercalciuria. N Engl J Med 311:73-80, 1984
13. Kaplan RA, Haussler MR, Deftos LJ, et al: The role of 1 alpha 25 dihydroxyvitamin D in the mediation of intestinal hyperabsorption of calcium in primary hyperparathyroidism and absorptive hypercalciuria. J Clin Invest 59:756-760,1977
14. Shen FH, Baylink DJ, Nielsen RL, et al: Increased serum 1,25-dihydroxyvitamin D in idiopathic hypercalciuria. J Lab Clin Med 90:955-962, 1977
15. Gray RW, Wilz DR, Caldas AE, et al: The importance of phosphate in regulating plasma 1,25 (OH)2 vitamin D levels in humans: Studies in healthy subjects, in calcium stone formers, and in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 45:299-306, 1977
16. Coe FL, Parks JH, Bushinsky DA, et al: Chlorthalidone promotes mineral retention in patients with idiopathic hypercalciuria. Kidney Int 33:1140-1146, 1988
17. Li X, Tembe V, Horwitz GM, et al: Increased intestinal vitamin D receptor in genetic hypercalicuric rats: A cause of intestinal calcium reabsorption. J Clin Invest 91:661-663, 1993
18. Laerum E, Larsen S: Thiazide prophylaxis,of urolithiasis: A double-blind study in general practice. Acta Med Scand 215:383-389, 1984
19. Ettinger B, Citron JT, Livermore B, et al: Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139:679-684, 1988
20. Pak CY, Delea CS, Banter FC: Successful treatment of recurrent nephrolithiasis (calcium stones) with cellulose phosphate. N Engl J Med 290:175-180, 1974
21. Lemann JJ, Litzow JR, Lennon EJ: The effects of chronic acid loads in normal man: Further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis. J Clin Invest 45:1608-1614, 1966
22. Lemann JJ, Adams ND, Gray RW: Urinary calcium excretion in human beings. N Engl J Med 301:535-541, 1979
23. Bushinsky DA, Krieger NS, Geisser DI, et al: Effects of pH on bone calcium and proton fluxes in vitro. Am J Physiol 245:F204-F209, 1983
24. Bushinsky DA, Lechleider RJ: Mechanism of protoninduced bone calcium release: Calcium carbonate-dissolution. Am J Physiol 253:F998-1005, 1987
25. Lemann JJ, Litzow JR, Lennon El: Studies of the mechanism by which chronic metabolic acidosis augments urinary calcium excretion in man. J Clin Invest 46:1318-1328, 1967
26. Lemann JJ, Pleuss JA, Hornick L, et al: Dietary NaClrestriction prevents the calciuria of KCl-deprivation and blunts the calciuria of KHCO3- deprivation in healthy adults. Kidney Int 47:899-906, 1995
27. Favus MJ: Intestinal absorption of calcium, magnesium, and phosphorus, in Coe FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York, NY, Raven Press, 1992, pp 57-82
28. Yanagawa N, Lee DBN: Renal handling of calcium and phosphorus, in Coe FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York, NY, Raven Press, 1992, pp 3-40
29. Coe FL, Bushinsky DA: Pathophysiology of hypercalciuria. Am J Physiol 247:F1-13, 1984
30. Coe FL, Parks JH: Primary hyperparathyroidism, in Coe FL, Parks JH (eds): Nephrolithiasis: Pathogenesis and Treatment (ed 2). Chicago, IL, Year Book Medical Publishers, 1988, pp 59-107
31. Marx SJ, Brandi ML: Familial primary hyperparathy-roidism, in Peck \VA (ed): Bone and Mineral Research, vol 5. Amsterdam, Elsevier, 1987, pp 375-407
32. Hodgkinson A, Marshall RW: Changes in the composition of urinary tract stones. Investigative Urology 13:131-135, 1975
33. Peacock M, Marshall RW, Robertson WG, et al: Renal stone formation in primary hyperparathyroidism and idiopathic stone disease, diagnosis, etiology and treatment, in Finlayson B, Thomas WC (eds): Colloquium on Renal Lithiasis. Gainesville, FL, Gainesville University Press of Florida, 1976, pp 339-355
34. Parks J, Coe F, Favus M: Hyperparathyroidism in nephrolithiasis. Arch Intern Med 140:1479-1481, 1980
35. McGeown MG: Effect of parathyroidectom on the incidence of renal calculi. Lancet 1:586-587, 1961
36. Deaconson TF, Wilson SD, Lemann J: The effect of parathyroidectomy on the recurrence of nephrolithiasis. Surgery 102:910-912, 1987
37. Ronni-Sivula H, Sivula A: Long-term effect of surgical treatment on the symptoms of primary hyperparathyroidism. Annals of Clinical Research 17:141-147, 1985
38. Lafferty FV, Hubay CA: Primary hyperparathyroidism: a review of the long-term surgical and nonsurgical morbidities as a basis for a rational approach to treatment. Arch Intern Med 149:780-796, 1989
39. Kaplan EL, Tanaka R, Younes N: Primary hyperparathyroidism, in Coe FL, Favus MJ, Pak CYC, (eds): Kidney Stones: Medical and Surgical Management. Philadelphia, PA, Lippincott-Raven, 1996, pp 803-820
40. Parks JH, Coe FL: A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30:85-90, 1986
41. Minisola S, Rossi W, Pacitti MT, et al: Studies on citrate metabolism in normal subjects and kidney stone patients. Miner Electrolyte Metab 15:303-308, 1989
42. Hamm LL: Citrate handling by the kidney. Kidney Int 38:728-735, 1990
43. Simpson DP: Citrate excretion: A window on renal metabolism. Am J Physiol 244:F223-F234, 1983
44. Pak CYC: Citrate and renal calculi. Miner Electrolyte Metab 13:257-266, 1987
45. Hamm LL, Alpern RJ: Regulation of acid-base balance, citrate, and urine pH, in Coe FL, Favus MJ, Pak CYC, et al (eds): Kidney Stones: Medical and Surgical Management. Philadelphia, PA, Lippincott-Raven, 1996, pp 289-302
46. Tiselius H: Solution chemistry of supersaturation, in Coe FL, Favus MJ, Pak CYC, et al (eds): Kidney Stones: Medical and Surgical Management. Philadelphia, PA, Lippincott-Raven, 1996, pp 33-64
47. Buckalew VM Jr: Calcium nephrolithiasis and renal tubular acidosis, in Coe FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York, NY, Raven Press, 1992, pp 729-756
48. Coe FL, Parks JH: Calcium phosphate stones and renal tubular acidosis, in Coe FL, Parks JH (eds): Nephrolithiasis: Pathogenesis and Treatment (ed 2). Chicago, IL, Year Book Medical, 1988, pp 139-171
49. Pak CYC, Holt K: Nucleation and growth of brushite and calcium oxalate in urine of stone formers. Metabolism 25:665-673, 1976
50. Pak CYC, Hayashi Y, Finlayson B, et al: Estimation of the state of supersaturation of brushite and calcium oxalate in urine: a comparison of three methods. J Lab Clin Med 89:891-909, 1977
51. Tiselius H: A simplified estimate of the ion-activity product of calcium phosphate in urine. Eur Urol 10:191-195, 1984
52. Finlayson B: Calcium stones: Some physical and clinical aspects, in David DS (ed): Calcium Metabolism in Renal Failure and Nephrolithiasis. New York, NY, John Wiley & Sons, 1977, pp 337-382
53. Robertson WG, Peacock M, Nordin BEC: Activity products in stone-forming and non-stone-forming urine. Clin Sei 34:579-594, 1968
54. Pak CYC, Eanes ED, Ruskin B: Spontaneous precipitation of brushite in urine: Evidence that brushite is the nidus of renal stones originating as calcium phosphate. Proc Natl Acad Sei USA 68/7:1456-4564, 1971
55. Pak CY, Sakhaee K, Fuller CJ: Physiological and physiochemical correction and prevention of calcium stone formation by potassium citrate therapy. Trans Assoc Am Physicians 96:294-305, 1983
56. Nicar MJ, Peterson R, Pak CYC: Use of potassium citrate as potassium supplement during thiazide therapy of calcium nephrolithiasis. J Urol 131:430-433, 1984
57. Butz M, Karadzic G, Dulce HJ: Prevention of calcium oxalate stones by alkaline treatment. Urol Res 12:40, 1984
58. Preminger GM, Sakhaee K, Skurla C, et al: Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol 134:20-23, 1985
59. Pak CY, Fuller C, Sakhaee K, et al: Long-term treatment of calcium nephrolithiasis with potassium citrate. J Urol 134:11-19, 1985
60. Barcelo P, Wuhl O, Servitge E, et al: Randomized double-blind study of potassium citrate in idiopathic hypocitraturic calcium nephrolithiasis. J Urol 150:1761-1764, 1993
61. Coe FL, Parks JH: Stone disease in hereditary distal renal tubular acidosis. Ann Intern Med 93:60-61, 1980
62. Coe FL, Parks JH, Asplin JR: The pathogenesis and treatment of kidney stones: Medical progress. N Engl J Med 327:1141-1152, 1992
63. Jaeger P, Portmann L, Jacquet A, et al: Influence of the calcium content of the diet on the incidence of mild hyperoxaluria in idiopathic renal stone formers. Am J Nephrol 5:40-44, 1985
64. Hayashi Y, Kaplan RA, Pak CYC: Effect of sodium cellulose phosphate therapy on crystallization of calcium oxalate in urine. Metabolism 24:1273-1278, 1975
65. Smith LH: Hyperoxaluric states, in Coe FL, Favus MJ (eds): Disorders of Bone and Mineral Metabolism. New York, NY, Raven Press, 1992, pp 707-728
66. Worcester EM: Stones due to bowel disease, in Coe FL, Favus MJ, Pak CYC, et al (eds): Kidney stones: Medical and Surgical Management. Philadelphia, PA, Lippincott-Raven, 1996, pp 883-904
67. Dobbins JW, Binder HJ: Effect of bile salts and fatty acids on the colonie absorption of oxalate. Gastroenterology 70:1096-1100, 1976
68. Kathpalia SC, Favus MJ, Coe FL: Evidence for size and charge permselectivity of rat ascending colon: Effects of ricinoleate and bile salts on oxalic acid and neutral sugar transport. J Clin Invest 74:805-811, 1984
69. Smith LH, Fromm H, Huffman AF: Acquired hyperoxaluria, nephrolithiasis and intestinal disease. N Engl J Med 286:1371, 1972
70. Dowling RH, Rose GA, Sutor DJ: Hyperoxaluria and renal calculi in ileal disease. Lancet 1:1103, 1971
71. Halverson JD, Wise L, Wazna MF, et al: Jejunoileal bypass for morbid obesity. Am J Med 64:461-475, 1978
72. Gelbart DR, Brewer LL, Fajardo LF, et al: Oxalosis and chronic renal failure after intestinal bypass. Arch Intern Med 137:239-243, 1977
73. Buchwald H, Varco RL, Matts JP, et al: Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia: Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH) [see comments]. N Engl J Med 323:946-955, 1990
74. Buchwald H, Stoller DK, Campos CT, et al: Partial ileal bypass for hypercholesterolemia. 20- to 26-year follow-up of the first 57 consecutive cases. Ann Surg 212:318-333, 1990
75. Parks JH, Ruml LA, Pak CYC: Hypocitraturia, in Coe FL, Favus MJ, Pak CYC, et al (eds): Kidney Stones: Medical and Surgical Management. Philadelphia, PA, Lippincott-Raven, 1996, pp 905-920
76. Vainder M, Kelly J: Renal tubular dysfunction secondary to Jejunoileal bypass. JAMA 235:1257-1258, 1976
77. Drenick EJ, Stanley TM, Border WA, et al: Renal damage with intestinal bypass. Ann Intern Med 89:594-599, 1978
78. Wharton R, D'Agati V, Magun AM, et al: Acute deterioration of renal function associated with enteric hyperoxaluria. Clin Nephrol 34:116-121, 1990
79. Coe FL, Parks JH: Hyperoxaluric states, in Coe FL, Parks JH (eds): Nephrolithiasis: Pathogenesis and Treatment (ed 2). Chicago, IL, Year Book Medical Publishers, 1988, pp 172-204
80. Coe FL, Raisen L: Allopurinol treatment of uric-acid disorders in calcium-stone formers. Lancet 1:129-131, 1973
81. Coe FL, Kavalach AG: Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 291:1344-1350, 1974
82. Pak CY, Arnold LH: Heterogeneous nucleation of calcium oxalate by seeds of monosodium urate. Proc Soc Exp Biol Med 149:930-932, 1975
83. Lonsdale K: Epitaxy as a growth factor in urinary calculi and gallstones. Nature 217:56-58, 1968
84. Lonsdale K: Human stones. Science 159:1199-1207, 1968
85. Deganello S, Chou C: The uric acid-whewellite association in human kidney stones. Scanning Electron Microscopy 3:927-933, 1984
86. Deganello S, Chou C: The uric acid-whewellite association in human kidney stones. Scanning Electron Microscopy 4:1545-1550, 1985
87. Pak CYC, Holt K, Britton F, et al: Assessment of pathogenetic roles of uric acid, monopotassium urate, monoammonium urate and monosodium urate in hyperuricosuria calcium oxalate nephrolithiasis. Miner Electrolyte Metab 4:130-136, 1980
88. Coe FL, Moran E, Kavalich AG: The contribution of dietary purine over-consumption to hyperpuricosuria in calcium oxalate stone formers. J Chronic Dis 29:793-800, 1976
89. Ettinger B, Tang A, Citron JT, et al: Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315:1386-1389, 1986